an inside out approach to prostate ablation profound medical is a canadian medical device company that has developed a unique and minimally invasive procedure to ablate the prostate gland in prostate cancer patients. profound’s novel technology combines real-time mr imaging with transurethral therapeutic ultrasound and closed-loop thermal feedback control. it provides a highly precise treatment tailored to patient-specific anatomy and pathology. this method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. the potential of this technology is currently being demonstrated in clinical trials. for more information, visit profoundmedical.com
Company profile
Ticker
PROF, PRN
Exchange
Website
CEO
Arun S. Menawat
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Profound Medical Inc.
SEC CIK
Corporate docs
PROF stock data
Latest filings (excl ownership)
6-K
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
22 Apr 24
6-K
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
9 Apr 24
40-F
2023 FY
Annual report (Canada)
7 Mar 24
6-K
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
6-K
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
4 Mar 24
6-K
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
27 Feb 24
6-K
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
15 Feb 24
6-K
Profound Medical Announces Non-Brokered Private Placement
16 Jan 24
6-K
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
3 Jan 24
6-K
Material Change Report
2 Jan 24
Transcripts
PROF
Earnings call transcript
2022 Q2
7 Aug 22
PROF
Earnings call transcript
2022 Q1
10 May 22
PROF
Earnings call transcript
2021 Q4
4 Mar 22
PROF
Earnings call transcript
2021 Q3
7 Nov 21
PROF
Earnings call transcript
2021 Q2
9 Aug 21
PROF
Earnings call transcript
2021 Q1
13 May 21
PROF
Earnings call transcript
2020 Q4
3 Mar 21
PROF
Earnings call transcript
2020 Q3
8 Nov 20
Latest ownership filings
144
Notice of proposed sale of securities
26 Mar 24
SC 13G/A
DASEKE DON R
13 Mar 24
SC 13G/A
GAGNON SECURITIES LLC
13 Feb 24
SC 13G/A
LETKO, BROSSEAU & ASSOCIATES INC
12 Feb 24
SC 13G/A
FIL Ltd
9 Feb 24
SC 13G
DASEKE DON R
11 Jan 24
SC 13G/A
GAGNON SECURITIES LLC
13 Feb 23
SC 13G/A
Flynn James E
10 Feb 23
SC 13G
LETKO, BROSSEAU & ASSOCIATES INC
10 Feb 23
SC 13G/A
FIL Ltd
9 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
32.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 3 |
Closed positions | 3 |
Increased positions | 9 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 75.46 bn |
Total shares | 7.95 mm |
Total puts | 5.00 k |
Total calls | 25.50 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Gagnon Securities | 1.58 mm | $16.14 bn |
FIL | 1.20 mm | $12.04 bn |
Letko, Brosseau & Associates | 1.16 mm | $11.35 bn |
Gagnon Advisors | 679.30 k | $6.93 bn |
Timelo Investment Management | 673.16 k | $6.87 bn |
Royce & Associates | 569.90 k | $5.71 bn |
Raymond James Financial Services Advisors | 550.71 k | $5.62 bn |
Genesys Ventures II | 455.74 k | $0.00 |
RY Royal Bank Of Canada | 401.83 k | $4.10 bn |
BAC Bank Of America | 182.41 k | $1.86 bn |
News
Alliance Global Partners Maintains Buy on Profound Medical, Lowers Price Target to $10.8
11 Mar 24
Stifel Maintains Hold on Profound Medical, Lowers Price Target to $9
8 Mar 24
Profound Medical: Q4 Earnings Insights
7 Mar 24
Profound Medical Q4 2023 GAAP EPS $(0.420) Misses $(0.330) Estimate, Sales $2.000M Beat $1.977M Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
Press releases
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
22 Apr 24
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
9 Apr 24
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
4 Mar 24
Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure
27 Feb 24